{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Non-Hodgkin+Lymphoma",
    "query": {
      "condition": "Aggressive Non-Hodgkin Lymphoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 165,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Non-Hodgkin+Lymphoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:20:09.582Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03246906",
      "title": "Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Aggressive Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Diffuse Large B-Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Prolymphocytic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent Waldenstrom Macroglobulinemia",
        "Hematologic and Lymphocytic Disorder",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-09-11",
      "completion_date": "2025-05-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03246906"
    },
    {
      "nct_id": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 42,
      "start_date": "2005-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244985"
    },
    {
      "nct_id": "NCT01434472",
      "title": "High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Indium In-111 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Yttrium Y-90 Ibritumomab Tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-11-16",
      "completion_date": "2020-05-06",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434472"
    },
    {
      "nct_id": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Ann Arbor Stage III Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage III Marginal Zone Lymphoma",
        "Ann Arbor Stage IV Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Marginal Zone Lymphoma",
        "Composite Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Richter Syndrome"
      ],
      "interventions": [
        {
          "name": "CD47 Antagonist ALX148",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2021-10-13",
      "completion_date": "2028-03-21",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025800"
    },
    {
      "nct_id": "NCT01787409",
      "title": "Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aggressive Non-Hodgkin Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Diffuse Large B-Cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Hepatosplenic T-Cell Lymphoma",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 565,
      "start_date": "2013-03-06",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787409"
    },
    {
      "nct_id": "NCT00310037",
      "title": "Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 151,
      "start_date": "2006-06",
      "completion_date": "2022-06",
      "has_results": true,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 48,
      "location_summary": "San Francisco, California • Bloomington, Illinois • Canton, Illinois + 26 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310037"
    },
    {
      "nct_id": "NCT01397825",
      "title": "MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "Transformed Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Burkitt's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Alisertib (MLN8237)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2011-08-09",
      "completion_date": "2016-10-05",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Burbank, California + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397825"
    },
    {
      "nct_id": "NCT03575351",
      "title": "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "JCAR017",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 184,
      "start_date": "2018-10-23",
      "completion_date": "2023-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 28,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03575351"
    },
    {
      "nct_id": "NCT00069966",
      "title": "Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "pixantrone dimaleate",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Theradex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-07",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069966"
    },
    {
      "nct_id": "NCT00807495",
      "title": "Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Burkitt's Lymphoma",
        "T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma",
        "Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2009-02-10",
      "completion_date": "2013-02-13",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-05-21T23:20:09.582Z",
      "location_count": 1,
      "location_summary": "Mount Holly, New Jersey",
      "locations": [
        {
          "city": "Mount Holly",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807495"
    }
  ]
}